Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, 32 Week Double-Blind, Parallel-Group, Multicenter Study to Compare the Efficacy and Safety of Initiating Treatment With Combination (Aliskiren/Amlodipine) Therapy in Comparison With the Sequential Add-on Treatment Strategies in Patients With Essential Hypertension.

Next Previous
Search
Trial Profile

A Randomized, 32 Week Double-Blind, Parallel-Group, Multicenter Study to Compare the Efficacy and Safety of Initiating Treatment With Combination (Aliskiren/Amlodipine) Therapy in Comparison With the Sequential Add-on Treatment Strategies in Patients With Essential Hypertension.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jan 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aliskiren/amlodipine (Primary) ; Aliskiren; Amlodipine
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Acronyms ACCELERATE
  • Sponsors Novartis

    • Most Recent Events

    • 24 May 2011 Results presented at the 26th Annual Scientific Meeting of the American Society of Hypertension.
    • 16 May 2011 Trial phase changed from III to IV as reported by ClinicalTrials.gov.
    • 13 Jan 2011 Results were published in the Lancet [online].

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top